Literature DB >> 6931620

Prediction of response to chemotherapy in acute myelocytic leukemia.

H D Preisler.   

Abstract

Marrow specimens obtained from 23 patients with acute myelocytic leukemia were exposed to cytosine arabinoside and/or daunorubicin in vitro, and the effects of these agents on colony formation in vitro was determined. Thymidine suicide indices were determined as well, which permitted a distinction to be made between kinetic and metabolic resistance to cytosine arabinoside. The sensitivity of the colony-forming cells to the two chemotherapeutic agents did not correlate with each other, indicating that sensitivity to each was independently determined. The relationship between in vitro sensitivity to daunorubicin and cytosine arabinoside and response to 25 courses of in vivo therapy with these two agents administered to 21 patients was determined. These studies indicated a clear-cut relationship between in vitro drug sensitivity and in vivo response with patients whose leukemic cells were sensitive to both agents entering complete remission, whereas patients whose leukemic cells were insensitive to one or both drugs in vitro failed to enter remission.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6931620

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia.

Authors:  Lili Aslostovar; Allison L Boyd; Mohammed Almakadi; Tony J Collins; Darryl P Leong; Rommel G Tirona; Richard B Kim; Jim A Julian; Anargyros Xenocostas; Brian Leber; Mark N Levine; Ronan Foley; Mickie Bhatia
Journal:  Blood Adv       Date:  2018-08-14

2.  Comparison of autoradiography and DNA histograms in assessing S-phase cells from patients with myeloid leukemias.

Authors:  A Raza; A S Raza; K Kuliczkowski; S C Zhao; H D Preisler
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

3.  Potential limitations of in vitro clonogenic drug sensitivity assays.

Authors:  G W Dong; H D Preisler; R Priore
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

4.  Single-cell mass cytometry adapted to measurements of the cell cycle.

Authors:  Gregory K Behbehani; Sean C Bendall; Matthew R Clutter; Wendy J Fantl; Garry P Nolan
Journal:  Cytometry A       Date:  2012-06-12       Impact factor: 4.355

Review 5.  The human tumor cloning assay in cancer drug development. A review.

Authors:  P Agre; T E Williams
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

6.  Cytostatic drug testing in human leukemias by means of multiparametric flow cytometry.

Authors:  A Neubauer; H Sauer; G Valet
Journal:  Blut       Date:  1987-11

7.  Kinetics and sensitivity of daunorubicin in patients with acute leukemia.

Authors:  M W DeGregorio; W M Holleran; B A Macher; C A Linker; J R Wilbur
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

8.  Uptake of adriamycin by human leukemic cells as measured by flow cytometry.

Authors:  H D Preisler; A Raza
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

9.  Adriamycin and cytosine arabinoside contribute equally to prediction of response in acute myelocytic leukemia with improved confidence level.

Authors:  M G Lihou; P J Smith
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

10.  Quantitative association between the in vitro human tumor stem cell assay and clinical response to cancer chemotherapy.

Authors:  T E Moon; S E Salmon; C S White; H S Chen; F L Meyskens; B G Durie; D S Alberts
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.